Exelixis
EXEL
#2080
Rank
โ‚ฌ6.93 B
Marketcap
24,31ย โ‚ฌ
Share price
0.45%
Change (1 day)
21.65%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Revenue for Exelixis (EXEL)

Revenue in 2024 (TTM): โ‚ฌ1.86 B

According to Exelixis's latest financial reports the company's current revenue (TTM) is โ‚ฌ1.81 B. In 2023 the company made a revenue of โ‚ฌ1.65 B an increase over the revenue in the year 2022 that were of โ‚ฌ1.50 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Exelixis from 2000 to 2024

Annual revenue

Year Revenue Change
2024 (TTM) โ‚ฌ1.86 B12.82%
2023 โ‚ฌ1.65 B10.23%
2022 โ‚ฌ1.50 B19.08%
2021 โ‚ฌ1.26 B56.13%
2020 โ‚ฌ0.80 B-6.27%
2019 โ‚ฌ0.86 B15.64%
2018 โ‚ฌ0.74 B97.65%
2017 โ‚ฌ0.37 B107.18%
2016 โ‚ฌ0.18 B434.56%
2015 โ‚ฌ34.04 M65.06%
2014 โ‚ฌ20.62 M-9.06%
2013 โ‚ฌ22.68 M-36.81%
2012 โ‚ฌ35.9 M-83.9%
2011 โ‚ฌ0.22 B59.91%
2010 โ‚ฌ0.13 B31.57%
2009 โ‚ฌ0.10 B26.89%
2008 โ‚ฌ83.53 M8.54%
2007 โ‚ฌ76.96 M2.92%
2006 โ‚ฌ74.77 M16.62%
2005 โ‚ฌ64.12 M83.42%
2004 โ‚ฌ34.96 M-15.27%
2003 โ‚ฌ41.26 M-2.69%
2002 โ‚ฌ42.39 M-8.68%
2001 โ‚ฌ46.43 M76.67%
2000 โ‚ฌ26.28 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
โ‚ฌ35.61 B 1,859.65%๐Ÿ‡ฌ๐Ÿ‡ง UK
โ‚ฌ46.14 B 2,439.09%๐Ÿ‡ซ๐Ÿ‡ท France
โ‚ฌ56.38 B 3,002.27%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ41.96 B 2,209.31%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ27.91 B 1,435.97%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ78.12 B 4,198.76%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ50.21 B 2,662.79%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ9.16 M-99.50%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ85.11 M-95.32%๐Ÿ‡บ๐Ÿ‡ธ USA